welcome
therapeutics to improve cardiovascular health
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.
recent news
01 Aug 2018
Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations MORE
26 Jul 2018
Amarin Announces Approval for Vascepa® in United Arab Emirates MORE
Stock Information
- Symbol:
- AMRN (NASDAQ)
- Quote:
- $3.02
- Change:
- +0.06
- Date:
- 4:00 PM EDT on Aug 16, 2018
Join Our Mailing List
You may automatically receive Amarin Corporation plc financial information by email.